DrugPatentWatch Database Preview
Alpharma Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for ALPHARMA PHARMS, and what generic alternatives to ALPHARMA PHARMS drugs are available?
ALPHARMA PHARMS has one approved drug.
There are nine US patents protecting ALPHARMA PHARMS drugs.
There are fifty-five patent family members on ALPHARMA PHARMS drugs in twenty-three countries.
Summary for Alpharma Pharms
| International Patents: | 55 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Alpharma Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-005 | Aug 13, 2009 | DISCN | Yes | No | 7,815,934 | Start Trial | Y | Start Trial | |||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-005 | Aug 13, 2009 | DISCN | Yes | No | 8,877,247 | Start Trial | Y | Start Trial | |||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-001 | Aug 13, 2009 | DISCN | Yes | No | 7,682,633 | Start Trial | Start Trial | ||||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-003 | Aug 13, 2009 | DISCN | Yes | No | 7,815,934 | Start Trial | Y | Start Trial | |||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-003 | Aug 13, 2009 | DISCN | Yes | No | 8,158,156 | Start Trial | Start Trial | ||||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-002 | Aug 13, 2009 | DISCN | Yes | No | 8,685,443 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alpharma Pharms
Paragraph IV (Patent) Challenges for ALPHARMA PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 60 mg/2.4 mg | ➤ Subscribe | 2010-05-25 |
| ➤ Subscribe | Extended-release Capsules | 30 mg/1.2 mg, 50 mg/2 mg and 80 mg/3.2 mg | ➤ Subscribe | 2010-05-28 |
| ➤ Subscribe | Extended-release Capsules | 100 mg/4 mg | ➤ Subscribe | 2010-05-03 |
International Patents for Alpharma Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5566102 | Start Trial |
| China | 1703200 | Start Trial |
| South Korea | 20150029762 | Start Trial |
| Australia | 2016238844 | Start Trial |
| European Patent Office | 2719378 | Start Trial |
| European Patent Office | 2034975 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
